8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported) – August 11, 2006

________________________

WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

_____________________

Pennsylvania	1-8036	23-1210010
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
101 Gordon Drive, PO Box 645, Lionville, PA		19341-0645
(Address of principal executive offices)		(Zip Code)

610-594-3319

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or address, if changed since last report)

____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

On August 11, 2006, West Pharmaceutical Services, Inc. (the “Company”) issued a press release announcing that the Company will presenting at the CJS Securities 6^th Annual Summer “New Ideas” Small-Cap Investor Conference on August 15, 2006 at 10:00 a.m. until approximately 10:35 a.m. EST. The event will be held at the Metropolis Country Club in White Plains, New York. William J. Federici, the Company’s Vice President and Chief Financial Officer, and Michael A. Anderson, the Company’s Vice President and Treasurer, will be presenting.

A copy of the Company’s presentation will be available through the Investor link at the Company’s website, http://www.westpharma.com and is also attached hereto as Exhibit 99.1. A copy of the press release is attached hereto as Exhibit 99.2. Both Exhibits are incorporated herein by reference.

The information in this report (including Exhibit 99.1 and 99.2) is being furnished pursuant to Item 7.01 Regulation FD and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

Item 9.01 Financial Statement and Exhibits

(d)	Exhibits
	Exhibit #	Description
	99.1	West Pharmaceutical Services, Inc. presentation.
	99.2	West Pharmaceutical Services, Inc. Press Release, dated August 11, 2006.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WEST PHARMACEUTICAL SERVICES, INC.

/s/ John R. Gailey III

John R. Gailey III

Vice President, General Counsel and Secretary

August 15, 2006

EX-99

William J. Federici

VP & Chief Financial Officer

Michael A. Anderson

VP & Treasurer

         Certain statements contained in this presentation and certain statements that may be made by management of the
Company orally during this presentation are forward-looking statements that set forth anticipated results based on
management’s plans and assumptions. Such statements give our current expectations or forecasts of future events – they do
not relate strictly to historical or current facts. In particular, these include statements concerning future actions, future
performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as
legal proceedings and financial results. We have tried, wherever possible, to identify such statements by using words such as
“estimate,” “expect,” “intend,” “believe,” “plan,” “anticipate” and other words and terms of similar meaning in connection with
any discussion of future operating or financial performance or condition.

         We cannot guarantee that any forward-looking statement will be realized. If known or unknown risks or uncertainties
materialize, or if underlying assumptions are inaccurate, actual results could differ materially from past results and those
expressed or implied in any forward-looking statement.  You should bear this in mind as you consider forward-looking
statements. We cannot predict or identify all such risks and uncertainties, but factors that could cause the actual results to
differ materially from expected and historical results include the following:  sales demand; timing and commercial success of
customers’ products incorporating our products and services, including specifically, the Exubera® Inhalation-Powder insulin
device; customers’ changes to inventory requirements and manufacturing plans that alter existing orders or ordering patterns
for our products; our ability to pass raw-material cost increases on to customers through price increases; maintaining or
improving production efficiencies and overhead absorption; physical limits on manufacturing capacity that may limit our ability
to satisfy anticipated demand; the availability of labor to meet increased demand; competition from other providers; the
successful integration of acquired businesses; average profitability, or mix, of products sold in a reporting period; financial
performance of unconsolidated affiliates; strength of the U.S. dollar in relation to other currencies, particularly the Euro, UK
Pound, Danish Krone, Japanese Yen and Singapore Dollar; higher interest rates; the availability and cost of property and
casualty insurance; interruptions or weaknesses in our supply chain, which could cause delivery delays or restrict the
availability of raw materials and key bought-in components and finished products, including products produced in northern
Israel;  raw-material price escalation, particularly petroleum-based raw materials, and energy costs; and availability, and pricing
of materials that may be affected by vendor concerns with exposure to product-related liability.

         We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future
events or otherwise.   

Safe Harbor Statement

Corporate Profile

World's premier manufacturer of
components and systems for
injectable drug delivery

Stoppers and seals for vials

Disposable components
used in syringe, IV, blood
collection and diagnostic
systems

Founded in 1923

HQ in Lionville, PA

2005 sales $700M

Market capitalization $1.2 Billion

Diverse Customer Base

Company Estimated Market Share: 70% in Pharma; 70% in Device; 95% in Biotech

32 manufacturing sites

34 sales offices

7 technical centers

6,000 employees worldwide

Global Presence

Key Company Developments

Acquisition of Monarch Laboratories

Acquisition of The Tech Group

Acquisition of Medimop

Sale of GFI Clinical Unit

Sale of Contract Manufacturing Operations

New management team

Restructuring and increased CAPEX

Sale of OTC Research Services Group

Kinston plant accident

Kinston restart

2-for-1 stock split

Divestiture of Drug Delivery

FY 2005

FY 2004

FY 2003

FY 2002

FY 2001

FY05 Net sales: Approx. $700 MM

Business Segments

Geographic Sales Mix(2005, based on point of sale)

West’s Competitive Edge

Unmatched experience/expertise: drug material
interface

Ability to source components from multiple
locations globally

Protected IP: West’s components and systems

Regulatory barrier to entry:  NDA and ANDA
filing must include reference to all
packaging/components in contact with the drug:

1.

West Drug Master File (DMF) 1546 is confidential

2.

West DMF includes functionality data (multi-year studies)

3.

All primary package changes require new stability/ functionality
studies for new filing

Diabetes

Components

for Pen System Applications

Components for

Traditional System
Applications

Devices

FluroTec^® and

BarrierCoatings

Westar^®
Processing

West Spectra^TM

Biotechnology/Oncology

Corporate Growth Strategy
Core Pharmaceutical Systems Business

Maximize the value of West’s core business   
(Company estimated market:  $1.1 BN)

Market segmentation

Generate maximum value from key growth drivers

New product innovation

Lean manufacturing

Geographic expansion

Strategic acquisitions

Medimop Medical Projects Ltd.

Corporate Growth Strategy
Tech Group Business

Build market share in multi-component systems
for drug delivery

(Company estimated market:  $4.5 BN)

Leverage customer base

Develop a portfolio of proprietary systems for injectable,
transmucosal, and pulmonary delivery

Pursue selected consumer opportunities

License or acquire innovative technologies

Pursue strategic acquisitions

The Tech Group

Investment Considerations

Established platform for sustainable growth

Significant barriers to entry

Favorable growth drivers in key market
segments

Global, diverse customer base

Global manufacturing capability

Strong, experienced management team

Strong corporate governance

   .12

-

-

-

-

-

Interest Payment

$1.15*

$1.40

$1.33

$1.32

   $.96

$.83

EPS Non-GAAP

-

-

(.02)

-

-

-

Affiliate Gain

-

-

    .30

(.42)

-

-

Kinston

-

-

-

-

(.03)

-

Foreign Currency

   (.02)

   .05

(.07)

-

(.09)

-

Unusual Tax
Items

-

(.04)

    .03

    .26

   .30

  .05

Restructuring

$1.05

$1.39

$1.09

$1.48

$.78

$.78

EPS Reported

1^st H 06

2005

2004

2003

2002

2001

GAAP/Non-GAAP Reconciliation

* Included in 2006 full-year non GAAP EPS guidance of $1.82- $1.88.

This information is being provided for the convenience of readers in making comparisons between the periods presented
and other periods

Second Quarter Results
($ in millions, except per share data)

$0.38

$0.62

E.P.S. from Continuing Operations

$0.37

$0.62

Non-GAAP E.P.S. from Continuing Operations

$12.2

$20.7

Income from Continuing Operations

$19.9

$32.1

Operating Profit

$31.9

$36.9

Selling, General & Administrative Expenses

    29%

29%

Gross Margin

  $173.0

$240.2

Net Sales

2005

2006

2005 E.P.S. from continuing operations includes a $0.03 charge related to the repatriation of funds
under AJCA and a $0.04 favorable impact related to the reversal of a restructuring reserve.

Capital Management

$118.8

$136.6

Working Capital

          $26.8

      YTD Spending

      Full Yr Expected - up to $95                                                     

Capital Expenditures:

45.0%

39.8%

     Debt to Total Invested Capital

$625.0

$652.7

Total Capitalization

$281.0

$259.9

Total Debt

12/31/05

6/30/06

($M)

Gross Margin Percentages

Debt Maturity Schedule
($ in millions)

Debt to Total Capitalization

Goal: 40-45% excluding acquisitions and significant capital expansion

Summary

West has a set of competitive advantages that
uniquely position the company for future growth

These competitive advantages capitalize on the
primary growth drivers in key market segments

Global, diverse customer base

Solid financial base

Strong, experienced management team focused
on execution

EX-99

Exhibit 99.2

Contacts: West Pharmaceutical Services, Inc. Michael A. Anderson Vice President and Treasurer (610) 594-3345 Investors and Financial Media: Financial Dynamics Julie Huang / Theresa Kelleher (212) 850-5600 wst@fd-us.com

WEST PHARMACEUTICAL SERVICES TO PRESENT AT THE CJS SECURITIES INVESTOR CONFERENCE

LIONVILLE, PA, August 11, 2006 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced that William Federici, Vice President and Chief Financial Officer, and Michael Anderson, Vice President and Treasurer, of West Pharmaceutical Services, Inc., will be presenting at the CJS Securities 6th Annual Summer "New Ideas" Small-Cap Investor Conference in White Plains, NY on August 15, 2006 at 10:00 a.m. A copy of the Company’s presentation from the conference will be available through the Investor link of the Company’s website, www.westpharma.com.

About West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc. is the world's leading manufacturer of components and systems for injectable drug delivery, including stoppers and seals for vials, and closures and disposable components used in syringe, IV and blood collection systems. West’s customers include the world’s leading pharmaceutical, biotechnology, generic drug and medical device producers. Internationally headquartered in Lionville, Pennsylvania, West supports its partners and customers from 50 locations throughout North America, South America, Europe, Mexico, Japan, Asia and Australia. For more information, visit West at www.westpharma.com.